Zenosense, Inc. announced the manufacturing of a pre-commercial prototype device to be evaluated for the detection of lung cancer in exhaled breath. Prototyping manufacture is well advanced. The work has been undertaken by the company's contracted development partner Zenon Biosystem, which is part of the Sgenia group.

In line with the protocol design for an anticipated lung cancer detection trial to be held in a clinical setting, two pre-commercial Devices are currently being manufactured of the same design to ensure reproducibility of results. The completed devices are expected to be ready during the second half of the current month. The device incorporates components designed to filter out Volatile Organic Compounds not of interest in order to optimize the detection of target VOC biomarkers found in exhaled breath and associated with the incidence of lung cancer.

These components and their elements include molecular sieves incorporated in complementary layered and mixed sensor structures to screen incoming VOCs, and nanometric sensing mesh to maximize the detective area. During this optimization process Zenon has developed new metal oxide materials and combinations of metal oxides that cannot be found in commercially available sensors. A complementary quartz crystal sensor employing a gas sorbent substrate has also been designed, along with a micro gas chromatography chip, for pre-detection screening.

All components are of a relatively low cost consistent with the Company's intent to create cost effective products.